These obtained results suggest the potential of H3R antagonists such as E169, with good in silico physicochemical properties and stable retained key interactions in docking studies at H3R, to simultaneously modulate disturbances in brain neurotransmitters and imbalanced in the Akt-mTOR signaling pathway related to neurodegenerative disorders, e.g., AD. This evidence concerns the gene HRH3 and Alzheimer disease.